How could Trevi Therapeutics' pursuit of chronic cough approval affect Eli Lilly and Company?
New chronic cough drug may increase competition for Eli Lilly Trevi Therapeutics is advancing its drug, Haduvio, through clinical trials for chronic cough indications, including refractory chronic cough (RCC). The company has aligned with the FDA on the development pathway for non-IPF-ILD-related chronic cough, planning a Phase II dose-ranging study with approximately 120 patients. If Haduvio receives FDA approval, it would introduce a new treatment option into the market. This development increases competitive pressure on Eli Lilly and Company, which operates in the broader pharmaceutical space, particularly in indications related to chronic lung conditions.
- Effect
- Mild negative
- How direct
- 2 steps, 1 inferred by Brind
- When
- Within months
- The story
- No new developments lately
How it reaches Eli Lilly and Company
-
As of September 30, 2026, the company reported $299.4 million in cash and marketable securities, up from $188.3 million at the end of 2025. The company stated its current cash runway is sufficient to fund lead clinical programs through potential FDA approval. Research and Development Expenses increased to $19.1 million, primarily due to costs for the OCEAN-1, OCEAN-2, and LAKE clinical trials.
The full event1independent outlet -
The company, Trevi Therapeutics, is funding three active clinical programs for Haduvio, including the LAKE Phase IIb Trial targeting refractory chronic cough (RCC). Management reported alignment with the FDA on the development pathway for non-IPF-ILD-related chronic cough, which will utilize a Phase II dose-ranging study.
1 report connects these two. Brind only summarizes; follow a link to read the reporting itself.
- aol.com Tuesday
-
legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective
Everything about company -
If Trevi Therapeutics successfully obtains FDA approval for Haduvio, it will introduce a new drug into the chronic cough market. This new market entrant increases competition for Eli Lilly and Company, which is a major player in the pharmaceutical industry, particularly in related therapeutic areas.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American pharmaceutical company
Everything about Eli Lilly and Company
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- Trevi Therapeutics is pursuing FDA approval for severe refractory chronic cough (RCC) and non-IPF-ILD chronic cough.aol.com
- The non-IPF-ILD market opportunity 'more than doubles the IPF potential' for Haduvio.aol.com
- The company plans to conduct a Phase II dose-ranging study with approximately 120 non-IPF-ILD patients.aol.com
- The company noted the absence of active competitive programs in their target indications following recent clinical failures in the RCC space.aol.com
Why it matters
The chronic cough market represents a significant unmet medical need, as patients in target populations experience up to 1,500 coughs per day, leading to higher risks of morbidity and hospitalization. The success of a drug like Haduvio could capture a large segment of this market, especially given the company's stated intent to retain global commercial rights.
Eli Lilly and Company, as a major pharmaceutical entity, operates in a highly competitive environment. The introduction of a successful, conditionally accepted drug like Haduvio could shift market dynamics, forcing competitors to adjust their strategies or face reduced market share in chronic cough indications.
What we don't know yet
- Will the LAKE Phase IIb Trial for RCC confirm the necessary trial powering?
- How will the FDA respond to the Phase II dose-ranging study for non-IPF-ILD?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
- Center for Drug Evaluation and ResearchPossibleCDER's review workload increases as drug seeks approval for new chronic cough indications
- MerckPossibleNew chronic cough drug may increase competition for Merck
- CongressPossibleFDA's support for new chronic cough drugs may influence future regulatory mandates
- Drug Enforcement AdministrationPossibleNew nalbuphine formulation may require DEA oversight for chronic cough
- United States of AmericaPossibleNew chronic cough drug approval could set new standards for US patient care.
Reporting
- aol.comTuesday
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.